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Introduction: Auricular low-level transcutaneous vagus nerve stimulation (aLL-tVNS) has emerged as a promising technology for
cardiac arrhythmia management but is still experimental. In this physiological study, we hypothesized that aLL-tVNS modulated
the autonomic nervous balance through a reduction of sympathetic tone and an increase in heart rate variability (HRV). We
investigated the muscle sympathetic nerve activity (MSNA) recorded by microneurography during vagally-mediated aLL-tVNS and
active control on healthy volunteers.
Methods: In this crossover, double-blind controlled study, healthy men (N=28; 27 ± 4 years old) were assigned to aLL-tVNS applied to
cymba and lobe (active control) of the right ear. Each participant was randomly allocated to the three sequences (5Hz, 20Hz and
active control-5Hz) during one session. MSNA signal was recorded at rest, during voluntarily apnea and aLL-tVNS. Sympathetic
activity was expressed as: 1) number of bursts per minute (burst frequency: BF) and 2) MSNA activity calculated as BF x mean
burst amplitude and expressed as changes from baseline (%). RR intervals, HRV parameters and sympathetic activity were
analyzed during 5min-baseline, 10min-stimulation and 10min-recovery periods. Mixed regression models were performed to
evaluate cymba-(5Hz-20Hz) effects on the parameters with stimulation.
Results: During apnea and compared to baseline, BF and MSNA activity increased (p =0.002, p =0.001, respectively). No stimulation
effect on RR intervals and HRV parameters were showed excepted a slightly increase of the LF/HF ratio with stimulation in the
cymba-5Hz sequence (coef. ± SE: 0.76 ± 0.32%; p=0.02). During stimulation, reductions from baseline in BF (Coef. ± SE: -4.8 ± 1.1,
p<0.001) was observed but was not statistically different from that one in the active control. Reduction of MSNA activity was not
significantly different between sequences.
Conclusion: Acute right cymba aLL-tVNS did not induce any overall effects neither on heart rate, HRV nor MSNA variables on healthy
subjects when compared to active control. Interestingly, these findings questioned the role of active controls in medical device
clinical trials that implied subjective endpoints.
  
 Contribution to the field
Autonomic nervous system (ANS) disbalance is one of the crucial determinants for atrial fibrillation pathogenesis. With its
non-invasive approach, auricular low-level vagus nerve stimulation (aLL-tVNS) appears as a promising technology to manage
patients suffering from paroxysmal atrial fibrillation. Nevertheless, physiological effects on sympathovagal balance remain to be
fully understood before standardizing the use of tVNS devices for clinical applications. Mediated effects implying afferents auricular
vagal projections would result in a reduction of sympathetic tone and an increase in heart rate variability (HRV). Our original
research is the first one that explored the directs effects of aLL-tVNS on ANS in a randomized, crossover, sham-controlled and
double-blind study. As muscle sympathetic nerve activity (MSNA) directly assesses the sympathetic ganglionic neuron activity, we
hypothesized that aLL-tVNS lowered the sympathetic activity measured by microneurography on healthy volunteers. We reported
for the first time the results of two tested frequencies (5Hz-20Hz) compared to an active sham in a crossover design. Although our
results did not demonstrate any consistent aLL-tVNS effects on HRV, they provide substantial feedback on ONS response to aLL-tVNS












 Studies involving animal subjects
Generated Statement: No animal studies are presented in this manuscript.
  
 Studies involving human subjects
Generated Statement: The studies involving human participants were reviewed and approved by Ethics Committee Hospitalo-
Facultaire Saint-Luc-UCL, Brussels, Belgium
and Ethics Committee Erasme Hospital, Brussels, Belgium. The patients/participants provided their written informed consent to
participate in this study.
  
 Inclusion of identifiable human data
Generated Statement: No potentially identifiable human images or data is presented in this study.
  
 Data availability statement








 Sympathetic effect of auricular transcutaneous vagus nerve stimulation  1 
on healthy subjects: a crossover controlled clinical trial comparing vagally-2 
mediated and active control stimulation using microneurography 3 
 4 
Anaïs Gauthey* (MD)1; Sofia Morra (MD)2; Philippe van de Borne (MD, PhD)2; Denis 5 
Deriaz (MSc)3, Nathalie Maes4, Jean-Benoît le Polain de Waroux (MD, PhD)5 6 
 7 
*Anaïs Gauthey and Sofia Morra equally contributed to this work. 8 
 9 
 10 
Authors department: 11 
 12 
1Department of Cardiology, Saint-Luc Hospital, Université Catholique de Louvain, Belgium 13 
2Department of Cardiology, Erasme Hospital, Université Libre de Bruxelles, Belgium 14 
3 Department of Biomedical and Preclinical Sciences, Université de Liège, Liège, Belgium 15 
4Department of Biostatistic and Medico-Economic Information, CHU Hospital of Liège, 16 
Belgium 17 
5Department of Cardiology, AZ Sint Jan, Bruges, Belgium 18 
 19 
 20 
First and Corresponding author:  21 
Gauthey Anaïs  22 
E-mail: anaisgauthey@gmail.com 23 
 24 
Keywords: auricular transcutaneous vagus nerve stimulation, auricular branch of the vagus 25 
nerve, heart rate variability, healthy subjects, sham, muscle sympathetic nerve activity, cardiac 26 
autonomic function. 27 
 28 
Word count: 3899 29 
 30 








Introduction: Auricular low-level transcutaneous vagus nerve stimulation (aLL-tVNS) has 3 
emerged as a promising technology for cardiac arrhythmia management but is still 4 
experimental. In this physiological study, we hypothesized that aLL-tVNS modulated the 5 
autonomic nervous balance through a reduction of sympathetic tone and an increase in heart 6 
rate variability (HRV). We investigated the muscle sympathetic nerve activity (MSNA) 7 
recorded by microneurography during vagally-mediated aLL-tVNS and active control on 8 
healthy volunteers.  9 
 10 
Methods: In this crossover, double-blind controlled study, healthy men (N=28; 27 ± 4 years 11 
old) were assigned to aLL-tVNS applied to cymba and lobe (active control) of the right ear. 12 
Each participant was randomly allocated to the three sequences (5Hz, 20Hz and active control-13 
5Hz) during one session. MSNA signal was recorded at rest, during voluntarily apnea and aLL-14 
tVNS. Sympathetic activity was expressed as: 1) number of bursts per minute (burst frequency: 15 
BF) and 2) MSNA activity calculated as BF x mean burst amplitude and expressed as changes 16 
from baseline (%). RR intervals, HRV parameters and sympathetic activity were analyzed 17 
during 5min-baseline, 10min-stimulation and 10min-recovery periods. Mixed regression 18 
models were performed to evaluate cymba-(5Hz-20Hz) effects on the parameters with 19 
stimulation. 20 
 21 
Results: During apnea and compared to baseline, BF and MSNA activity increased (p =0.002, 22 
p =0.001, respectively). No stimulation effect on RR intervals and HRV parameters were 23 
showed excepted a slightly increase of the LF/HF ratio with stimulation in the cymba-5Hz 24 
sequence (coef. ± SE: 0.76 ± 0.32%; p=0.02). During stimulation, reductions from baseline in 25 
BF (Coef. ± SE: -4.8 ± 1.1, p<0.001) was observed but was not statistically different from that 26 
one in the active control. Reduction of MSNA activity was not significantly different between 27 
sequences.  28 
 29 
Conclusion: Acute right cymba aLL-tVNS did not induce any overall effects neither on heart 30 
rate, HRV nor MSNA variables on healthy subjects when compared to active control. 31 
Interestingly, these findings questioned the role of active controls in medical device clinical 32 





Cardiac autonomic disbalance represents a prerogative for the onset and maintenance of 38 
atrial fibrillation (AF).1-4 Atrial ganglionated plexus ablation in addition or not to pulmonary 39 
veins (PV) isolation, has demonstrated a significant benefit for free-recurrence of atrial 40 
fibrillation.5,6 Auricular low level transcutaneous vagus nerve stimulation (aLL-tVNS) has been 41 
described to inhibit ganglionated plexus and stellate activities. Cholinergic anti-inflammatory 42 
pathway mediated by tVNS involves a reduction in pro-inflammatory cytokines levels. 7 Also, 43 
aLL-tVNS increases atrial and PV myocardial refractory periods. 7,8 Concordantly, this 44 
technique is susceptible to modulate both the trigger and substrate for AF along with autonomic, 45 
electrical and structural atrial remodelings,9,10. Nevertheless, physiological effects on 46 
sympathovagal balance remain to be fully understood before standardizing the use of tVNS 47 
devices for clinical applications. Feasibility of aLL-tVNS as a reliable alternative to invasive 48 
cervical VNS is driven by the cutaneous distribution of vagal fibers through its auricular branch 49 






imaging (fMRI).11-13 Published randomized and non-randomized aLL-tVNS studies on 1 
cardiovascular effects in healthy subjects11,14 are attractive but would require to be validated by 2 
controlled designs with direct assessment of orthosympathetic activity. Muscle sympathetic 3 
nerve activity (MSNA) assessed by the microneurography, records directly the sympathetic 4 
activity directed toward peripheral blood vessels while analysis of HRV indirectly reflects 5 
changes in cardiac parasympathetic activity.15-17 As potential explanation for aLL-tVNS 6 
mechanisms, excitatory signals from afferents vagal fibers to the nucleus of the solitary tract 7 
(NTS) and caudal ventrolateral medulla (CVLM) would result in both a reduction and an 8 
increase in sympathetic and parasympathetic tones respectively.14 Inhibitory signals from 9 
CVLM to the rostro ventrolateral medulla (RVLM), well described as the mainstay of 10 
sympathetic output sent inhibitory signals to the sympathetic paravertebral ganglionic chain 11 
resulting in a decrease in sympathetic activity. 18 In this crossover, double-blind controlled 12 
study, we focused on acute and direct effects of aLL-tVNS on sympathetic tone. As MSNA 13 
directly assesses the sympathetic ganglionic neuron activity19, we hypothesized that aLL-tVNS 14 
lowered the sympathetic activity measured by microneurography. For this purpose, we 15 
investigated the MSNA signal recorded by microneurography during cymba aLL-tVNS and 16 
active control on healthy volunteers. 17 
 18 
 19 
MATERIALS AND METHODS 20 
 21 
Study design 22 
 23 
This was a clinical experimental, double-blind with crossover-controlled study. All the 24 
participants were tested for 3 sequences: cymba-(5Hz-20Hz) stimulation along with active 25 
control (earlobe-5Hz) in a simple randomly allocated order. Prior to each session, randomness 26 
of the assignment to one of the sequences was determined throwing a dice. Thus, there were in 27 
total six possible combinations. The random list for the sequences (one number of the dice 28 
corresponding to one combination of sequences) has been established prior to the first 29 
participant session. Each phase (baseline, stimulation and recovery times) of each sequence 30 
(cymba-5Hz; cymba-20Hz and earlobe-5Hz) for all participants dataset received a random 31 
allocated alphanumerical code so that operators were blinded for the inspection of the 32 
neurogram. Statistical analyzes were fully blinded to the operators and performed by the 33 
biostatisticians (D.D. and N.M.). 34 
 35 
Participants and data  36 
 37 
Healthy, young and active men (27 ± 4 years old) were enrolled (N=28) from June 2019 until 38 
November 2019 in one single center by the two investigators. Only male gender was included  39 
based on the following considerations: 1) avoiding confounding contribution of menstrual cycle 40 
on the measurements; 2) easier identification of peroneal in men probably due to lower amount 41 
of subcutaneous fat20 and 3) lower resting MSNA activity reported in women.21 Candidates 42 
were eligible if they did not have any cardiovascular nor neurological nor mental diseases and 43 
if they did not take any medication. They had to be over 18 years of age and they were asked 44 
to avoid intense exercise and alcohol, and were asked to refrain from smoking and taking 45 
caffeine the day before participation. Prior to the experimental session, participants were asked 46 
to empty their bladder. Our local ethics committee (P2019/264; 2017/14JUI/317) approved the 47 






HRV analyzes were available for all the subjects (N=28). Successful recording rate for MSNA 1 
signal identification was 64% (N=18/28) with a good signal to noise ratio (5Hz: N=16/18; 2 




First, we assessed the muscle sympathetic nerve activity (MSNA) using the microneurography 7 
technique. Participants underwent subsequent aLL-tVNS either performed on the cymba of the 8 
right ear applying low frequency (5Hz) and high frequency (20Hz) stimulation and on the lobe 9 
of the right ear applying low frequency (5Hz) in a randomly order. They were blinded for 10 
assignment. Each sequence included a 5min-baseline followed by a 10min-stimulation and a 11 
10min-recovery (wash-out) phases along with continuous MSNA recording (Figure 1). During 12 
the session and in between all the three sequences, the adequacy of the nerve recording site was 13 
acertained by means of voluntary end-expiratory sustained apnea performed by participants 14 
with a subsequent increase in the MSNA activity (Figure 2). The duration of the apnea differed 15 
between individuals; each of them was required to hold his breath as long as he could (from a 16 
minimum of 13 seconds to a maximum of 49 seconds). The aim of this maneuver was to induce 17 
modification of blood gases concentration to activate the MSNA and to make sure the needle 18 
was correctly placed, and the obtained record coincided with MSNA activity and not with 19 
SSNA one. The identification of the apnea was based on the respiratory signal measured with 20 
the respiratory belt: the beginning of the apnea was identified at the end of a maximal 21 
expiration, the lungs being at their residual volume, the end of the apnea was identified prior to 22 
the restauration of respiration. 23 
 24 
Sample size calculation was limited by the lack of reliable and objective effect size for 25 
physiological tVNS impact either on cardiac autonomic function (HRV markers) and peripheral 26 
sympathetic tone (MSNA). Several considerations could participate to the varied tVNS 27 
response reported in the literature: 1) the inter-subject variability could limit the reproducibility 28 
of the results along with 2) the heterogeneity among tVNS protocols (setting parameters); 3)  29 
the need for more tVNS studies evaluating the sympathetic markers such as MSNA and 4) the 30 
complexity of the autonomic nervous system and clinical covariates that limited the evaluation 31 
of a one size effect-parameter. Nonetheless, we performed this study using a crossover design 32 
with each subject being its own control, requiring a smaller cohort to achieve outcomes and 33 
allowing for precise description of the intervention effect. 34 
 35 
 36 
Statistical methods 37 
 38 
Outcomes measured were: 1) direct comparison of the changes in RR intervals, HRV, blood 39 
pressure and MSNA parameters between cymba-aLL-tVNS (5Hz-20Hz) and active control 40 
sequence (earlobe-5Hz); 2) correlation between the variation of MSNA activity (%baseline) 41 
and RMSSD, SDRR or the LF/HF ratio. 42 
 43 
Distribution of continuous variables were graphically checked at each phase level for HRV 44 
variables and at minute level for both BP and MSNA variables. Both outliers’ observations 45 
(N=3) and artifacts (0.78% of the pooled MSNA recordings) were dropped out for statistical 46 
analysis.  Continuous variables were expressed as means and standard deviations (mean  SD) 47 
and categorical variables were reported as counts and proportions. SDRR (ms), LF and HF 48 
components (ms2) and MSNA (AU/s) were log-transformed. Mixed linear regression models 49 
were used to analyze the stimulation effect on the evolution of variables with stimulation.  50 





For each variable, models included the sequence effect (active control- 5Hz= reference, cymba-1 
5Hz and cymba-20Hz), the stimulation effect (baseline= reference, and stimulation), and the 2 
stimulation*sequence effect. Random subject intercepts were added to the models in order to 3 
take into account the subject-specific variation. For the active control-5Hz, cymba-5Hz and 4 
cymba-20Hz stimulation, effect delay was tested by dividing the stimulation phase in two 5 5 
minutes subphases. Pearson correlations between the variation of MSNA activity (%baseline) 6 
and RMSSD, SDRR or the LF/HF ratio were also computed. Data analysis was carried out 7 
using R software (version 3.6.2) and SAS software (version 9.4) and results were considered 8 
significant at the 5% critical level (p<0.05). 9 
 10 
Transcutaneous vagus nerve stimulation 11 
 12 
Low frequency (5Hz) and high frequency (20Hz) stimulation with a fixed pulse duration of 13 
0.2ms were delivered using a tVNS system dedicated to target the right cymba and the earlobe.  14 
Earlobe, currently used as the standard not vagally-mediated site in fMRI studies12,13,22-24 was 15 
considered for active control sequence. 11 Subject’s right ear was cleaned and dried so that a 16 
good contact between earpiece and skin was ensured. Individually intensity level (mA) was 17 





Firstly used in the mid 60’s to record action potentials on peripheral human nerves, 23 
microneurography directly assesses the efferent sympathetic activity directed to vascular 24 
smooth muscle of vessels called muscle sympathetic nerve activity (MSNA).27,28 The 25 
equipment was composed of:  two tungsten needle electrodes  (µm), an amplifier to increase 26 
the raw signal and improved signal to noise ratio, a signal integrator  (GRASS, Instrumental 27 
division, Astro-Med®) and an output (computer software-ADInstrument).29 Subjects were 28 
tested at rest in a semi-supine position with a pillow under the head and a supported pillow 29 
under the right leg so that the site of stimulation remained stable for all the experiment. The 30 
experimental session was realised in a dedicated room with temperature controlled.  31 
First part of the session consisted in peroneal nerve of the right leg identification by cutaneous 32 
electrical stimulation. 29-31 Then, an active micro electrode (UNA35F2S, FHC Neural 33 
MicroTargeting™) was inserted into the peroneal nerve which was preferentially choosen to 34 
record MSNA because of its easy accessibility. The reference electrode was placed in the 35 
subcutaneous tissue 2-3cm away from the active one. Electrode adjustements and 36 
audiomonitoring were made until a clear MSNA signal was achieved. Establishement of the 37 
MSNA signal was assessed on real time using the following criteria: 1)  diastolic-pulsed-38 
synchronized, 2) no influence of startle nor sensory stimuli and 3) respiratory modulated.16 Raw 39 
signal was processed to be amplified, filtered, integrated and connected to the acquisition 40 
system PowerLab 16/30 (ADInstruments). To avoid the unwanted noise of electrical stimulus 41 
from 5 to 20Hz frequency stimulations, an automatic band-pass filter was applied. Each burst 42 
was manually identified by a trained operator. The amplitude of each burst was determined 43 
(arbitrary units: AU). Required amplitude of the normalized signal had to be at least a 2:1 signal 44 
to noise ratio, as previously described29. Burst frequency (number of burst/min), burst incidence 45 
(BI; bursts/100 heart beats) and MSNA activity were reported. Burst amplitude varied along 46 
with amplification and nerve position among subjects. MSNA activity was calculated as burst 47 
frequency multiplied by mean burst amplitude (AU) expressed in percentage from baseline 48 
value to allow inter-participant comparison. 32 49 
  50 





Others data acquisition 1 
 2 
One lead-ECG, systemic blood pressure, oxygen saturation and respiratory ampliation signals 3 
were continously assessed during the experimental session (Figure 1). Breathing was free (173 4 
breath/min). Prior to HRV analysis, adequate R peak detection was manually checked. Beat-to-5 
beat RR interval analysis was automatically processed using the Heart rate variability (HRV) 6 
module for LabChart Pro v8 (ADInstruments) after exclusion of ectopic beats. A 1000-Hz 7 
sampling frequency was set by default for HRV analysis. 8 
Standard deviation of RR intervals (SDRR) and root mean square of the successive RR interval 9 
differences (RMSSD) were used for time-domain analysis. Low (LF), high (HF) frequency 10 
power and LF/HF ratio were used for frequency-domain measurements. 16 33Beat-to-beat 11 
systemic blood pressure was acquired by a finger cuff (Finometer Pro, FMS©, Amsterdam, the 12 
Netherlands) and analyzed off-line through the Blood Pressure Module for LabChart 13 
(ADInstruments).  Brachial blood pressure was measured using an automatic manometer to 14 
confirm finometer values. Oxygen saturation and respiratory ampliation signal were obtained 15 
using a pulse oximeter (Capnostream-35-monitor ©, Oridion Medical 272 Ltd, Jerusalem, 16 






All participants (N=28) were healthy young men with baseline characteristics reported in Table 23 
1. Mean stimulation intensities at cymba-(5Hz-20Hz) and active control-5Hz were 1.5±0.6mA, 24 
1.2±0.5mA and 5.5±1.6mA respectively which is concordant with others studies.24-26 During 25 
apnea and compared to baseline, burst frequency and MSNA activity increased (p=0.002; 26 
p=0.001 respectively) which specifically featured effective sympathetic tone modulation in 27 
response to breathing cessation. At the beginning of the apnea, there is a suppression of the 28 
sympathetic nerve activity without discernable bursts. HR accelerates compared to normal 29 
respiration and systolic blood pressure slightly falls. Towards the end of the apnea, a marked 30 
rise in the sympathetic nerve activity is observed, characterized by an increase of BF and 31 
MSNA. HR slows and systolic blood pressure rises compared to the beginning of the apnea 32 
(Figure 2). 33 
 34 
Stimulation effects of the 3 sequences on parameters  35 
 36 
• Effects of aLL-tVNS on heart rate variability 37 
 38 
No overall stimulation effect on RR intervals nor HRV parameters was demonstrated excepted 39 
in the LF/HF ratio (cymba-5Hz). LF/HF ratio was significantly lower in the cymba-5Hz (Coef. 40 
± SE: -0.54 ± 0.23, p=0.021) and increased significantly with stimulation in this sequence 41 
(Coef. ± SE:0.76±0.32; p=0.020). HF was significantly lower in the cymba-20Hz sequence and 42 
no stimulation effect was noted. LF was significantly lower in the cymba-(5Hz-20Hz) 43 
sequences and no stimulation effect was noted (Table 2 and Figure 3). No effect delay during 44 
stimulation was observed (p-values>0.05 for all parameters).  45 
 46 
 47 
• Effects of aLL-tVNS on blood pressure parameters 48 
 49 
No stimulation effect was observed for all the blood pressure variables. (Table 2) 50 





• Effects of aLL-tVNS on MSNA parameters 1 
During stimulation, reductions from baseline in BF (Coef. ± SE: -4.8 ± 1.1, p<0.001) was 2 
observed.  However, this evolution was not statistically different from that one in the active 3 
control (Table 2 and Figure 4). Reduction of MSNA activity was not statistically significant 4 
(Table 2) We did not find any correlation between MSNA activity and HRV parameters.  5 
 6 
For additional information regarding descriptive statistics, see supplementary data (additional 7 
Table 1). 8 
 9 
DISCUSSION  10 
 11 
• Results summary  12 
 13 
To the best of our knowledge, our study is the first to explore the specific aLL-tVNS effects on 14 
sympathetic tone using microneurography compared to active control in crossover trial with 15 
randomly allocated stimulation sequences. Our results did not demonstrate any overall effects 16 
of cymba aLL-tVNS neither on HRV nor MSNA variables compared to active control (earlobe 17 
sequence-5Hz). Interestingly, an active control response may also be suggested.  18 
 19 
• Heterogeneous response of autonomic nervous system to stimuli 20 
 21 
HRV analysis is currently used for clinical assessment of cardiac autonomic function with the 22 
assumptions that LF and HF power reflect sympathetic and vagal modulation respectively. 23 
Also, the LF/HF ratio has been suggested as an index for sympathovagal balance. 15,16  24 
Obviously, interpretation of those HRV parameters remains questionable since they are indirect 25 
indexes of the autonomic balance at the cardiac level.  For each of them, LF and HF components 26 
resulted in a mix and variable proportion of orthosympathetic (ONS) and parasympathetic 27 
(PNS) systems. 16,33 Same LF/HF ratio values could refer to different fluctuations of PNS or 28 
ONS or both of them. Also, varying effects between the two systems should not be considered 29 
as reciprocal. Indeed, heterogeneous response like “diving reflex” with observed bradycardia 30 
along with activated ONS clearly indicated the complexity of the relationship between the two 31 
pathways34. Therefore the clinical significance of LF/HF ratio has not been yet fully clarified.35 32 
LF/HF ratio has been shown to be reduced by aLL-tVNS which is associated with improved 33 
HRV in healthy humans.14 In contrast, in the present study, we identified a slightly increase in 34 
the LF/HF ratio during the cymba-5Hz stimulation compared to active control (earlobe-5Hz) 35 
suggesting a potential shift toward a sympathetic predominance. However, an important remark 36 
concerned the context which remained crucial for HRV measurements interpretation:1) LF/HF 37 
ratio was significantly lower (cymba-5Hz) compared to active control (Table 2 and Figure 3) 38 
and 2) a more sensitive perception of the stimulus when applied to cymba versus ear lobe could 39 
participate to explain the observed shift in the autonomic balance. Therefore, the clinical 40 
conclusion relative to this result may be not relevant. Further and for all the three sequences, 41 
no correlation was found between HRV parameters and MSNA activity highlighting the 42 
complexity to accurately interpret those variations mediated by two different systems 43 
(autonomic cardiac and peripheral sympathetic activities). Noteworthily, aLL-tVNS effects on 44 
HRV are hard to carry out since mixed results exist in the literature probably due to the variety 45 
of study designs, control groups, protocols and stimulation parameters, etc.  Finally, although 46 
our results did not demonstrate any consistent aLL-tVNS effects on HRV, they provide 47 







• Variability among aLL-tVNS studies on cardiac autonomic system 1 
 2 
Compared to Clancy el al14, we report higher baseline values for spectral HRV parameters. 3 
However, our participants were younger, healthy and exclusively active male. These 4 
characteristics are well known to be associated with LF power and SDRR.25,33,36 Variability 5 
among aLL-tVNS parameters (frequencies, site of stimulation and intensity levels, etc.) could 6 
also play a role in the heterogeneity of the results observed in the literature. In their elegant 7 
review11, Butt et al. summarized the different settings and findings of aLL-tVNS studies 8 
focusing on cardiovascular parameters among healthy subjects. As underscored by the authors, 9 
the various results observed on HRV could be related to differences among the stimulation 10 
protocols.14,25 Beyond parameters, the location of auricular stimulation sites also differs 11 
between the different studies. We used a device designed to target the cymba as this region is 12 
exclusively innervated by ABVN with a more expected impact on HRV and strong evidence of 13 
vagal activated projections.24,25,37 In contrast, others used tragus-dedicated systems.7,14  With 14 
the right vagus nerve destinated to the sinoatrial node and the left one dedicated to 15 
atrioventricular node, the stimulation side is also a potential source of discrepancy. As we 16 
wanted to specifically explore effects on heart rate variability, we decided to target the right 17 
cymba25. Control group also varies with either inactive or active aLL-tVNS14,22,25. Also, 18 
stimulation settings (intensity levels, pulse width, frequency, duration of the stimulus, etc.) 19 
ranged widely. As De Couck et al.25, we used a personalized thresholding to define intensity 20 
level but others refer to a “set stimulation method” in which intensity was determined by the 21 
operator.26  Two frequencies of stimulation (5Hz and 20Hz) were tested in our study based on 22 
the following considerations. Vagus nerve is composed of afferent (80%) and efferent (20%) 23 
fibers with a majority of C fibers activated at low frequency stimulation (5Hz) and high 24 
intensity level (mA)8,37. Nonetheless, fibers nerve composition differs between vagus nerve and 25 
ABVN, the latter containing more A fibers themselves activated at higher frequency (20Hz)38. 26 
But others have recommended the frequency of 10Hz (pulse width:500s) for its major 27 
reduction of heart rate.39 Several explanations for the lack of differences during stimulation 28 
between sequences could be suggested: 1) an active control response to aLL-tVNS cannot be 29 
excluded. The latter also questioned the implication of subjective endpoints to explain the 30 
observed results; 2) our healthy and active population may have challenged the modulation of 31 
a “normal” autonomic state; 3) settings parameters might have been not optimal to activate 32 
afferent vagal pathway but higher intensities would have led to discomfort; and 4) the small 33 
number of participants could have limited the results.  34 
 35 
• Active control response of aLL-tVNS 36 
 37 
Using the crossover design with active control stimulation performed on the earlobe, we 38 
observed a signification reduction in BF during stimulation, but this was not related neither to 39 
stimulation frequency nor to site of stimulation. Strongly supported by an accurate modulation 40 
of ONS illustrated by MSNA changes during apnea, these results are in favor of a sympathetic 41 
mediated effect. We did not identify any predictors for the active control response. Validating 42 
an effect during the active control sequence would have implied a direct comparison with a “no 43 
treatment” sequence.40 Nonetheless, taking into account that our study was initially designed to 44 
compare cymba aLL-tVNS versus ear lobe aLL-tVNS, we may questioned the subjective 45 
outcomes in the observed results. Some relevant points could be pointed out: 1) active control 46 
with crossover along with MSNA protocols are lacking. Indeed, active control aLL-tVNS is not 47 
systematic14,25 as well as MSNA recording. 26,41 Published aLL-tVNS studies on cardiovascular 48 
parameters are promising but comparison with active control stimulation would help to validate 49 






control, confounding variates influences are limited. From statistical considerations, this allows 1 
for smaller sample size. As sequences were randomized, order effect is excluded. We checked 2 
if the results were robust to the order of sequence attribution adding a categorical variable to 3 
the regression models. Also, each sequence was composed of a baseline and recovery periods 4 
which has the advantage to manage carry-over effects. aLL-tVNS studies conventionally 5 
explored the potential effect of aLL-tVNS compared to control but not in the reverse way. 2) 6 
Ear lobe as a reliable site for active control stimulation12,13,22 may be questioned despite its 7 
innervation free from vagal fibers.42 Indeed, changes in BOLD signal induced by ear lobe 8 
transcutaneous stimulation in healthy subjects has been documented through fMRI studies11. 9 
Published activation brain maps for several ear location stimulation, highlighted that earlobe 10 
projections overlap with cymba projections for some cortical areas. However, NTS nor locus 11 
coeruleus, two major targets for tVNS mechanisms were concerned by this crossing 12,24.  Ear 12 
lobe is definitively not physiologically inert challenging tVNS methodology in clinical trials. 13 
We could mention cymba as ABVN dedicated region to be used for both active and control 14 
stimulation but with different settings.43 15 
 16 
 17 
• Active control design for aLL-tVNS medical devices 18 
As the present work was designed to demonstrate a specific effect of tVNS on autonomic 19 
balance, we included an active control sequence (earlobe-5Hz) not vagally-mediated and a 20 
crossover design as a control strategy. We questioned here the role of controls in clinical trials 21 
with non-invasive medical devices like tVNS that implied subjective endpoints. This should be 22 
integrated to methodology to test the efficacy of tVNS itself that would not be reliable to a 23 
relaxation state of the subjects. Question may be clinically relevant as well as feasibility with 24 
no additional risk making that active control ethically acceptable.44 Effectiveness of aLL-tVNS 25 
devices should clearly be distinguished from active control effect/subjective outcomes before 26 
approval and commercial use of the technique.45 The importance of controlled design certainly 27 
made sense to improve the understandings of aLL-tVNS mechanisms so that optimal 28 





This study has several limitations. First, the small number of participants might have been 34 
insufficient to demonstrate aLL-tVNS impact on sympathetic tone (type II error) but this had 35 
to be integrated with the technical challenge of MSNA acquisition. Second, carryover effect 36 
could have not been excluded despite the wash out period of 10 min whom duration was limited 37 
by the required stability of the active needle inserted into the peroneal nerve around subdermal 38 
tissues to obtain high quality signal of MSNA. 39 
We observed a response during active control sequence, but this could be questioned, as active 40 
control may not be free from specific effect. Although study design was focused on active aLL-41 
tVNS rather than on control effect, we discussed this with limited bias using a crossover-42 
controlled design. Second, all our subjects were healthy and young men so no extrapolation 43 
could be made for other groups (women, elderly, etc.) and particularly for patients with cardiac 44 
arrhythmia. Third, despite prior cleaning of the ear, skin properties could have limited the 45 
delivery of the electrical signal. Also, even if participant were asked to breath constantly, 46 
respiration rate fluctuations could have influenced HRV parameters. Finally, active maneuvers 47 
such as standing and/or tilt test could have been an alternative to evaluate the effects of aLL-48 








Acute right cymba aLL-tVNS did not induce overall effects neither on heart rate, HRV nor 3 
MSNA variables on healthy subjects compared to active control. These findings questioned the 4 
role of active controls in medical device clinical trials that implied subjective endpoints.   5 
 6 
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RR (ms): time interval between two successive R-waves of the QRS 
HR (beats/min): heart rate  
MSNA: muscle sympathetic nerve activity 
BMI (kg/m2): body mass index 
SBP (mmHg): systolic blood pressure  
DBP (mmHg): diastolic blood pressure 
MAP (mmHg): mean blood pressure 
aLL-tVNS: auricular low-level transcutaneous vagus nerve stimulation 
RMSSD (ms): root mean square of the successive RR interval differences  
SDRR (ms): standard deviation of RR intervals 
LF power (%): relative power of the low frequency band (0.04-0.15Hz) 
LF power (ms2): absolute power of the low frequency band 
HF power (%): relative power of the high frequency band (0.15-0.4Hz) 
HF power (ms2): absolute power of the high frequency band 
LF/HF (%): ratio of the LF-to-HF power 
BF (bursts/min): number of bursts per minute  
MSNA activity (%): burst frequency multiplied by mean burst amplitude (AU) expressed in 
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Figure 1. Study design 
Consecutive sequences (active control (5Hz), aLL-tVNS-5Hz; aLL-tVNS-20Hz) were randomly 
ordered and composed of 5min-baseline, 10min-stimulation and 10min-recovery phases. Apnea were 









Figure 2.  MSNA variations during baseline and voluntary end-expiratory apnea. Normal 
respiration during baseline (53s length), maximal voluntary end-expiratory apnea (21s length) and 
normal respiration during recovery (60s) are illustrated. From top to bottom: ECG; blood pressure (BP); 
neurogram and respiration. Towards the end of the apnea, a marked rise in the sympathetic nerve activity 











Figure 3. During all the consecutive aLL-tVNS sequences (active control-5Hz, aLL-tVNS-5Hz, 
aLL-tVNS-20Hz), evolution (mean SD) of heart rate (A), RR interval (B), RMSSD (C), LF/HF 
ratio (D), LF (E) and HF (F) components  per phase (baseline, stimulation and recovery). No 
stimulation effect on RR intervals and HRV parameters were showed excepted a slightly increase 











Figure 4. During all the consecutive aLL-tVNS sequences (active control-5Hz, aLL-tVNS-5Hz, 
aLL-tVNS-20Hz), evolution (mean SD) of burst frequency (A) and MSNA activity (%) (B) per 
phase (baseline, stimulation, recovery).  During stimulation, reductions from baseline in BF (Coef. 
± SE: -4.8 ± 1.1, p<0.001) was observed but was not statistically different from that one in the 


















Table 1. Participants baseline characteristics  
Variable Mean ± SD or n (%) 
Male, n (%) 28 (100%) 




23.5 ± 3.2 
 
SBP (mmHg) 126 ± 10 
DBP (mmHg) 72 ± 6 
MAP (mmHg) 





























Table 2: Study of aLL-tVNS effects (Linear Mixed Model)   
Independent variable Coefficient ± SE p-value 
HR, bpm Intercept 61.7 ± 1.6 - 
 5-Hz stimulation sequence (ref=control) -0.3 ± 0.6 0.57 
 20-Hz stimulation sequence (ref=control) -0.2 ± 0.6 0.77 
 Stimulation phase (ref=baseline phase) -1.1 ± 0.6 0.09 
 5-Hz stim sequence * Stim phase 0.7 ± 0.9 0.42 
 20-Hz stim sequence * Stim phase 0.9 ± 0.9 0.28 
    
RMSSD, ms Intercept 47.7 ± 4.7 - 
 5-Hz stimulation sequence (ref=control) -0.2 ± 2.1 0.93 
 20-Hz stimulation sequence (ref=control) -1.3 ± 2.1 0.53 
 Stimulation phase (ref=baseline phase) 0.2 ± 2.1 0.91 
 5-Hz stim sequence * Stim phase 0.7 ± 2.9 0.82 
 20-Hz stim sequence * Stim phase -1.4 ± 2.9 0.64 
    
SDRR, ms Intercept 70.5 ± 4.9  - 
 5-Hz stimulation sequence (ref=control) -7.2 ± 3.0 0.020 
 20-Hz stimulation sequence (ref=control) -6.2 ± 3.0 0.043 
 Stimulation phase (ref=baseline phase) -3.1 ± 3.0 0.31 
 5-Hz stim sequence * Stim phase 6.7 ± 4.3 0.12 
 20-Hz stim sequence * Stim phase 1.0 ± 4.3 0.81 
    
LF component,  Intercept 7.41 ± 0.21 - 
ms2* 5-Hz stimulation sequence (ref=control) -0.33 ± 0.16 0.036 
 20-Hz stimulation sequence (ref=control) -0.31 ± 0.16 0.048 
 Stimulation phase (ref=baseline phase) -0.11 ± 0.16 0.48 
 5-Hz stim sequence * Stim phase 0.27 ± 0.22  0.23 
 20-Hz stim sequence * Stim phase 0.17 ± 0.22 0.44 
    
HF component,  Intercept 6.86 ± 0.21 - 
ms2* 5-Hz stimulation sequence (ref=control) -0.08 ± 0.11 0.48 
 20-Hz stimulation sequence (ref=control) -0.25 ± 0.11 0.025 
 Stimulation phase (ref=baseline phase) -0.01 ± 0.11 0.92 
 5-Hz stim sequence * Stim phase -0.002 ± 0.153 0.99 
 20-Hz stim sequence * Stim phase -0.09 ± 0.15 0.56 
    
LF/HF ratio,  Intercept 2.18 ± 0.25 - 
% power ratio 5-Hz stimulation sequence (ref=control) -0.54 ± 0.23 0.021 
 20-Hz stimulation sequence (ref=control) -0.15 ± 0.23 0.52 
 Stimulation phase (ref=baseline phase) -0.34 ± 0.23 0.14 
 5-Hz stim sequence * Stim phase 0.76 ± 0.32 0.020 
 20-Hz stim sequence * Stim phase 0.26 ± 0.32 0.42 
    
SBP, mmHg Intercept 114.7 ± 2.0 - 
 5-Hz stimulation sequence (ref=control) 1.0 ± 1.1 0.39 
 20-Hz stimulation sequence (ref=control) -0.1 ± 1.1 0.93 
 Stimulation phase (ref=baseline phase) 0.2 ± 1.1 0.87 
 5-Hz stim sequence * Stim phase -1.3 ± 1.6 0.42 
 20-Hz stim sequence * Stim phase -0.3 ± 1.6 0.86 






DBP, mmHg Intercept 58.5 ± 1.7  - 
 5-Hz stimulation sequence (ref=control) 0.5 ± 0.7 0.47 
 20-Hz stimulation sequence (ref=control) 0.3 ± 1.7 0.64 
 Stimulation phase (ref=baseline phase) -0.1 ± 0.7 0.89 
 5-Hz stim sequence * Stim phase -0.3 ± 1.0 0.75 
 20-Hz stim sequence * Stim phase 0.2 ± 1.0 0.84 
    
MBP, mmHg Intercept 77.2 ± 1.7  - 
 5-Hz stimulation sequence (ref=control) 0.6 ± 0.8 0.41 
 20-Hz stimulation sequence (ref=control) 0.2 ± 0.8 0.82 
 Stimulation phase (ref=baseline phase) 0.0 ± 0.8 0.99 
 5-Hz stim sequence * Stim phase -0.6 ± 1.1 0.57 
 20-Hz stim sequence * Stim phase 0.0 ± 1.1 0.97 
    
BF, bursts per  Intercept 17.6 ± 2.7 - 
minute 5-Hz stimulation sequence (ref=control) 1.4 ± 1.1 0.21 
 20-Hz stimulation sequence (ref=control) -1.5 ± 1.1 0.19 
 Stimulation phase (ref=baseline phase) -4.8 ± 1.1 <0.001 
 5-Hz stim sequence * Stim phase 0.5 ± 1.6 0.75 
 20-Hz stim sequence * Stim phase 1.3 ± 1.6 0.41 
    
MSNA activity,  Intercept 3.95 ± 0.20 - 
AU/min* 5-Hz stimulation sequence (ref=control) 0.12 ± 0.10 0.21 
 20-Hz stimulation sequence (ref=control) -0.09 ± 0.10 0.34 
 Stimulation phase (ref=baseline phase) -0.13 ± 0.10 0.19 
 5-Hz stim sequence * Stim phase -0.06 ± 0.14 0.66 
 20-Hz stim sequence * Stim phase -0.003 ± 0.139 0.99 
*Models are predicting the log-transformed variable  










Additional table 1: Changes on HR, HRV, blood pressure and MSNA parameters 
     
Variable n Baseline Stimulation  Recovery 
HR, bpm 
 
   
    Active control (5Hz) 28 61.7 ± 8.4 60.6 ± 7.7 61.0 ± 7.4 
    aLL-tVNS-5Hz 28 61.3 ± 9.2 61.0 ± 8.7 61.5 ± 8.3 
    aLL-tVNS-20Hz 28 61.5 ± 8.3 61.4 ± 8.3 61.9 ± 8.0 
     
RMSSD, ms     
    Active control (5Hz) 28 47.7 ± 25.8 47.9 ± 24.8 48.5 ± 25.6 
    aLL-tVNS-5Hz 28 47.5 ± 25.4 48.4 ± 26.5 49.0 ± 27.6 
    aLL-tVNS-20Hz 28 46.4 ± 23.3 45.3 ± 23.7 47.8 ± 24.5 
     
SDRR, ms     
    Active control (5Hz) 28 70.5 ± 29.7 67.4 ± 25.7 73.7 ± 28.3 
    aLL-tVNS-5Hz 28 63.3 ± 22.4 66.9 ± 27.7 71.0 ± 25.3 
    aLL-tVNS-20Hz 28 64.3 ± 25.0 62.3 ± 24.7 72.0 ± 28.4 
     
LF component, ms2 
   
 
    Active control (5Hz) 28 3120 ± 3269 2392 ± 2662 2340 ± 2299 
    aLL-tVNS-5Hz 28 2222 ± 2887 2616 ± 3303 2818 ± 2979 
    aLL-tVNS-20Hz 28 1880 ± 1784 2104 ± 2131 2655 ± 2732 
     
HF component, ms2     
    Active control (5Hz) 28 1711 ± 2064 1541 ± 1760 1488 ± 1577 
    aLL-tVNS-5Hz 28 1789 ± 3201 1847 ± 3486 1891 ± 2421 
    aLL-tVNS-20Hz 28 1292 ± 1555 1416 ± 1630 1616 ± 1809 
     
LF component, % power     
    Active control (5Hz) 28 36.7 ± 17.8 33.1 ± 13.2 34.3 ± 12.7 
    aLL-tVNS-5Hz 28 35.9 ± 15.0 33.0 ± 13.9 32.7 ± 11.5 
    aLL-tVNS-20Hz 28 34.7 ± 14.0 34.1 ± 14.1 32.0 ± 14.4 
    
 
HF component, % power     
    Active control (5Hz) 28 20.5 ± 10.0 20.9 ± 9.3 20.8 ± 7.6 
    aLL-tVNS-5Hz 28 26.7 ± 11.2 21.2 ± 11.1 20.3 ± 9.9 
    aLL-tVNS-20Hz 28 21.8 ± 10.5 20.9 ± 9.1 18.9 ± 9.7 
     
LF/HF ratio, % power ratio     
    Active control (5Hz) 28 2.2 ± 1.4 1.8 ± 1.1 1.9 ± 1.0 
    aLL-tVNS-5Hz 28 1.6 ± 1.1 2.1 ± 1.5 2.0 ± 1.3 
    aLL-tVNS-20Hz 28 2.0 ± 1.5 2.0 ± 1.2 2.1 ± 1.5 
    
 






    Active control (5Hz) 28 115 ± 11 115 ± 12 114 ± 12  
    aLL-tVNS-5Hz 28 116 ± 11 115 ± 10 115 ± 10  
    aLL-tVNS-20Hz 28 115 ± 12 115 ± 10 115 ± 10  
      
DBP, mmHg     
     Active control (5Hz) 28 58 ± 9 58 ± 9 58 ± 10 
     aLL-tVNS-5Hz 28 59 ± 9 59 ± 9 59 ± 9 
     aLL-tVNS-20Hz 28 59 ± 9 59 ± 8 59 ± 9 
     
MBP, mmHg     
     Active control (5Hz) 28 77 ± 9 77 ± 10 77 ± 10 
     aLL-tVNS-5Hz 28 78 ± 9 77 ± 8 78 ± 9 
     aLL-tVNS-20Hz 28 77 ± 10 77 ± 8 77 ± 9 
     
BF, bursts per minute     
    Active control (5Hz) 16 17.6 ± 10.5 12.8 ± 10.1 16.1 ± 10.1 
    aLL-tVNS-5Hz 16 19.0 ± 10.5 14.7 ± 10.7 17.1 ± 9.8 
    aLL-tVNS-20Hz 15 16.1 ± 11.1 12.6 ± 11.8 17.9 ± 11.3 
     
MSNA activity (%)     
    Active control (5Hz) 16 100 89.4 ± 40.0 92.6 ± 27.5 
    aLL-tVNS-5Hz 16 100 81.3 ± 26.2 90.6 ± 25.6 
    aLL-tVNS-20Hz 15 100 87.3 ± 29.2 131.4 ± 29.5 
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